SAN DIEGO--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today ...

-- Results from this ongoing, noninterventional rollover study were presented at the 23rd Annual Society of Urological Oncology (SUO) Meeting in San Diego “LG-IR-NMIBC is a challenging disease to ...

Researchers sought to determine whether zanubrutinib plus obinutuzumab would be effective in treating patients with R/R FL. Researchers determined zanubrutinib plus obinutuzumab demonstrated sustained ...

Data support progressing obe-cel as a treatment for srSLE and 50M has been selected as the recommended Phase 2 dose. Autolus has aligned with U.S. Food and Drug Administration (FDA) on a Phase 2 trial ...

The decision to include median grades on transcripts was intended to reduce grade inflation. But the practice became a “bingo, bullseye, backfire," with its impact on grading standards, according to ...